A company has sparked significant controversy in the market.

Last night, a company called Haisheng Pharmaceutical, listed on the Beijing Stock Exchange, issued an announcement. In order to stabilize the stock price and protect the interests of investors, the actual controller of the company, Ye Shanhai and his daughter Ye Jin, planned to increase their holdings by 100 shares, with the planned amount not exceeding 1990 yuan.

Note, it's an increase of 100 shares, not ten thousand!

As soon as the news came out, it triggered heated discussions among investors. People have seen stingy behavior, but never this level of stinginess. Is this a way to give alms to a beggar or to vent some dissatisfaction through 100 shares?

While everyone was arguing fiercely, the announcement was retracted.

Advertisement

On the evening of March 5th, Haisheng Pharmaceutical issued an announcement titled "Regarding the Proposed Adjustment of Price Stabilization Measures and Apology":

"The company sincerely apologizes to the investors for not carefully formulating effective price stabilization measures in the past, and for not fully considering the impact on the market and investors." It also added, "The actual controller of the company applies for measures including but not limited to extending the share lock-up period, improving investor returns, etc., to stabilize the stock price."

So, what's the real story behind a listed company increasing its holdings by 100 shares?

In response, the listed company stated that according to the regulations of the Beijing Stock Exchange, if the public holding is less than 25% of the total share capital of the company, it will trigger the risk of delisting. Therefore, they could only buy 100 shares.

Are you confused? Let me explain it for you.The top three shareholders of the company, namely Ye Jinzhi, Wang Xiaoqing, and Ye Shanhai, are the actual controllers of Haisheng Pharmaceutical. The fourth largest shareholder, Quzhou Youming, is a company controlled by the actual controller Ye Shanhai. In other words, the top four shareholders hold a total of 59,999,900 shares, but according to the rules, they can hold up to 60,000,000 shares, which is 75% of the shares, otherwise it would not meet the listing conditions.

So, this is the reason the company stated, not that I don't want to increase my holdings, but I really can only increase by 100 shares. The implied meaning is that there is no problem with the company's announcement of increasing holdings, it just caused a misunderstanding among the majority of investors.

Isn't it amazing, friends? The stock price has broken the issue price, the listed company wants to increase its holdings, but it can't.

Speaking of this, it must be a bug in the rules.

Due to liquidity issues, many companies on the New Third Board have a very high shareholding ratio and lack public shareholders, which leads to a high shareholding ratio of non-public shareholders after the transfer to the Beijing Stock Exchange. And the exchange, in order to ensure liquidity, requires that the shareholding ratio of public shareholders be more than 25% of the total share capital after the issue. Otherwise, what about liquidity? What if someone manipulates the stock price?

So, the bug comes.

However, there is not no solution, some people have suggested that the actual controller of the company can first reduce shares, and then increase shares, which can avoid this restriction. It has to be said that our policy has always been to prevent how to reduce holdings, did not expect to increase holdings can also encounter trouble.

Let's talk about the basic situation of this company.

Haisheng Pharmaceutical was established in 2007, mainly engaged in the research and development and production of veterinary raw materials, pharmaceutical raw materials and intermediates. From 2019 to 2021, the company's business performance was very good, with operating income increasing from 145 million yuan to 269 million yuan, and net profit increasing from 29 million yuan to 117 million yuan.

But what about after that?In 2023, according to the preliminary performance report, Hai Sheng Pharmaceutical's operating income was 215 million yuan, a year-on-year decrease of 18.61%; net profit was 85.47 million yuan, a year-on-year decrease of 24.15%. Note that this is already the second consecutive year of decline!

On February 2nd, Hai Sheng Pharmaceutical was listed on the Beijing Stock Exchange with an issue price of 19.9 yuan per share, raising a total of 398 million yuan. However, as soon as the company went public, it immediately disclosed a performance forecast, stating that its performance had changed.

What do people think? Is this just a coincidence? Is the fundamental reason for the company's stock price falling below the issue price that the basic performance is not good enough?

Finally, what do people think about Hai Sheng Pharmaceutical's intention to increase its holdings? After all, as a listed company, it is aware that the maximum increase in holdings is only 100 shares, yet it insists on issuing an announcement to tease everyone, playing around.